# N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

> **NCT01260649** · PHASE4 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 17 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** ketamine
- **OTHER:** IV Saline
- **PROCEDURE:** ECT
- **DRUG:** Muscle Relaxant
- **DRUG:** Anesthetic Agents

## Key facts

- **NCT ID:** NCT01260649
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11-01
- **Primary completion:** 2012-10-26
- **Final completion:** 2012-11-01
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** lack of funding to cover staff salary (clinician and research coordinator)
- **Last updated:** 2017-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01260649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01260649, "N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01260649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*